Cyclic trans-phosphorylation in a homodimer as the predominant mechanism of EGFRvIII action and regulation

Despite intensive research no therapies targeted against the oncogenic EGFRvIII are present in the clinic. One of the reasons is the elusive nature of the molecular structure and activity of the truncated receptor. The recent publications indicate the EGF-bound wild-type EGFR to trans-phosphorylate...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Stec, Wojciech, Rosiak, Kamila, Treda, Cezary, Smolarz, Maciej, Peciak, Joanna, Pacholczyk, Marcin, Lenart, Anna, Grzela, Dawid, Stoczynska-Fidelus, Ewelina, Rieske, Piotr
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5823601/
https://ncbi.nlm.nih.gov/pubmed/29492217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24058
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares